UY35549A - FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR:Fc - Google Patents

FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR:Fc

Info

Publication number
UY35549A
UY35549A UY35549A UY35549A UY35549A UY 35549 A UY35549 A UY 35549A UY 35549 A UY35549 A UY 35549A UY 35549 A UY35549 A UY 35549A UY 35549 A UY35549 A UY 35549A
Authority
UY
Uruguay
Prior art keywords
fusion polypeptides
alternative formulations
tnfr fusion
tnfr
formulations
Prior art date
Application number
UY35549A
Other languages
English (en)
Inventor
Bañado Carlos
Bes Cédric
Raha Tamal
Original Assignee
Mabxience S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35549(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mabxience S A filed Critical Mabxience S A
Publication of UY35549A publication Critical patent/UY35549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas estables acuosas adecuadas para el almacenamiento de polipéptidos que contienen TNFR:Fc.
UY35549A 2013-05-02 2014-04-30 FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR:Fc UY35549A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166230 2013-05-02
EP13166228 2013-05-02
EP13180169 2013-08-13

Publications (1)

Publication Number Publication Date
UY35549A true UY35549A (es) 2014-11-28

Family

ID=50732113

Family Applications (2)

Application Number Title Priority Date Filing Date
UY35549A UY35549A (es) 2013-05-02 2014-04-30 FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR:Fc
UY0001035811A UY35811A (es) 2013-05-02 2014-10-31 FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR:Fc

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001035811A UY35811A (es) 2013-05-02 2014-10-31 FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR:Fc

Country Status (16)

Country Link
US (1) US20160106844A1 (es)
EP (1) EP2991668A1 (es)
JP (2) JP2016518386A (es)
KR (1) KR20160008575A (es)
CN (1) CN105873601A (es)
AU (1) AU2014261477A1 (es)
BR (1) BR112015027764A2 (es)
CA (1) CA2911068A1 (es)
EC (1) ECSP15050386A (es)
HK (1) HK1221163A1 (es)
MX (1) MX2015015051A (es)
RU (1) RU2663727C2 (es)
SG (1) SG11201508900UA (es)
TW (2) TW201534349A (es)
UY (2) UY35549A (es)
WO (1) WO2014177548A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
KR20180046888A (ko) 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
GB201717966D0 (en) * 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN110495447A (zh) * 2019-09-10 2019-11-26 湖南思为康医药有限公司 一种免疫细胞玻璃化冻存保护液及冻存免疫细胞的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311094T3 (es) * 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
AU2012244764B2 (en) * 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EA026226B1 (ru) * 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
SG11201401562RA (en) * 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
CN104661651A (zh) * 2012-07-09 2015-05-27 科荣生生物科学公司 表现出不溶性微粒显著减少的依那西普制剂
CA2889271A1 (en) * 2012-10-26 2014-05-01 Lupin Atlantis Holdings Sa Stable pharmaceutical composition of tnfr:fc fusion protein
WO2014078627A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins

Also Published As

Publication number Publication date
TW201534349A (zh) 2015-09-16
WO2014177548A1 (en) 2014-11-06
AU2014261477A1 (en) 2015-11-19
RU2015151606A (ru) 2017-06-06
KR20160008575A (ko) 2016-01-22
UY35811A (es) 2015-05-29
EP2991668A1 (en) 2016-03-09
TW201540321A (zh) 2015-11-01
CA2911068A1 (en) 2014-11-06
BR112015027764A2 (pt) 2017-08-29
JP2016518386A (ja) 2016-06-23
MX2015015051A (es) 2016-06-10
JP2018109064A (ja) 2018-07-12
SG11201508900UA (en) 2015-11-27
ECSP15050386A (es) 2015-12-31
RU2663727C2 (ru) 2018-08-08
CN105873601A (zh) 2016-08-17
US20160106844A1 (en) 2016-04-21
HK1221163A1 (zh) 2017-05-26

Similar Documents

Publication Publication Date Title
ECSP15050386A (es) FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
DOP2016000145A (es) Reguladores de nrf2
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CL2017000270A1 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
IN2015DN03029A (es)
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112015009462A2 (pt) composição farmacêutica estável do tnfr:fc proteína de fusão
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso
EA201501163A1 (ru) Модуляторы рецептора cxcr7
MY163236A (en) Polyethylene glycol-containing composition
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
EA201492280A1 (ru) Стабильный состав пексиганана